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1Supplement Figure 1:
Photomicrographs of a patient with marked histological improvement after 96 weeks of treatment. Panels A ( H&E,
400x) and B (Masson trichrome, 200x) from the pre-treatment biopsy show the classic features of steatohepatitis:
moderate steatosis, prominent ballooning injury, spotty lobular inflammation, and central perisinusoidal fibrosis.
Panels C ( H&E, 400x)  and D (Masson trichrome, 200x) from the post-treatment biopsy show improvement in all
features of steatohepatitis:  no ballooning injury, minimal steatosis, and rare foci of spotty inflammation with only
mild residual perisinusoidal fibrosis remaining.
Supplement Table 1. Baseline characteristics by treatment group
P*
Vitamin Vitamin E Pioglitazone Vitamin E
Placebo E Pioglitazone Total vs. vs. vs.
(n=83) (n=84) (n=80) (n=247) Placebo Placebo Pioglitazone
2
Demographics
Age (yrs) - mean±SD 45.4 46.6 47.0 46.3±11.9 0.59 0.43 0.83
Female (%) 57.8 61.9 58.8 59.5 0.59 0.91 0.68
Hispanic (%) 7.2 19.0 18.8 15.0 0.02 0.03 0.96
Non-white (%) 11.0 15.2 8.1 11.5 0.43 0.54 0.17
Quality of life† - mean±SD
SF-36 Physical component
Physical function 46 47  49 47±10  0.51  0.15  0.42
Role physical  46  48  49 48±11  0.26  0.08  0.49
Bodily pain  48  50  50 50±10  0.25  0.39  0.74
General health  42  44  43 43±10  0.26  0.32  0.90
Physical component summary 47 49 49 48±10 0.35 0.41 0.89
SF-36 Mental component
Vitality  42  45  45 44±11  0.13  0.16  0.93
Social function  47  50  49 49±10 0.24  0.41  0.73
Role emotional  47  49  51 49±11  0.34  0.02  0.20
Mental health  48  50  50 49±10  0.20  0.16  0.92
Mental component summary 47 49 49 48±10 0.10 0.10 0.96
Serum biochemistry tests - mean±SD
AST (U/L) 55 59 54 56±30 0.47 0.83 0.33
ALT (U/L) 81 86 82 83±49 0.51 0.90 0.58
GGT (U/L) 69 56 60 61±63 0.60 0.78 0.79
Alkaline phosphatase (U/L) 82 77 86 81±30 0.20 0.43 0.08
Bilirubin - direct (mg/dL) 0.14 0.13 0.16 0.15±0.12 0.99 0.57 0.59
Bilirubin - total (mg/dL) 0.76 0.75 0.77 0.76±0.35 0.48 0.86 0.61
Lipids - mean±SD
Triglycerides (mg/dL) 165 166 162 165±93 0.94 0.94 0.88
Total cholesterol (mg/dL) 199 195 195 196±39 0.62 0.49 0.84
High density lipoprotein (mg/dL) 43 44 45 44±12 0.98 0.73 0.75
Low density lipoprotein (mg/dL) 125 119 120 122±34 0.27 0.25 0.99
Metabolic characteristics - mean±SD
HOMA-IR (mg/dL x ìU/mL/405) 5.5 5.2 5.0 5.2±4.3 0.78 0.47 0.68
Fasting serum glucose (mg/dL) 95 95 92 94±13 0.79 0.16 0.10
Fasting serum insulin (ìU/mL) 23 22 21 22±18 0.68 0.76 0.91
Weight (kg) 99 94 97 97±23 0.13 0.49 0.42
Body mass index (kg/m ) 35 34 34 34±7 0.28 0.65 0.512
Waist circumference (cm) 109 107 108 108±14 0.35 0.60 0.69
Waist to hip ratio 0.93 0.93 0.94 0.93±0.08 0.81 0.65 0.82
Triceps skinfold (mm) 34 32 34 33±13 0.09 0.95 0.10
Mid-upper arm circumference (cm) 36 35 36 36±5 0.29 0.72 0.45
Trunk (% fat)‡ 42 42 43 42±8 0.57 0.95 0.52
Total (% fat)‡ 40 39 40 39±9 0.69 0.90 0.58
Supplement Table 1. Baseline characteristics by treatment group
P*
Vitamin Vitamin E Pioglitazone Vitamin E
Placebo E Pioglitazone Total vs. vs. vs.




None 19.3 16.9 13.8 16.7 0.67 0.40 0.63
Mild, zone 3 perisinusoidal 16.9 27.4 25.0 23.1
Moderate, zone 3 perisinusoidal 12.0 10.7 18.8 13.8
Portal/periportal only 1.2 1.2 3.8 2.0
Zone 3 and periportal 27.7 21.7 23.8 24.4
Bridging 19.3 20.5 13.8 17.9
Cirrhosis 3.6 1.2 1.2 2.0
Grade - mean±SD 1.6 1.5 1.4 1.5±1.0
Diagnosis of steatohepatitis (%)
No 10.8 8.4 12.5 10.5 0.49 0.59 0.07
Borderline, zone 3 pattern 16.9 9.6 22.5 16.2
Borderline, zone 1 pattern 1.2 1.2 0.0 0.8
Definite 71.1 80.7 65.0 72.5
Steatosis (%)
< 5% 2.4 2.4 1.2 2.0 0.65 0.65 0.85
5 - 33% 31.3 33.3 28.8 31.2
34 - 66% 42.2 33.3 37.5 37.6
> 66% 24.1 31.0 32.5 29.2
Grade - mean±SD 1.9 1.9 2.0 1.9±0.8
Amount (foci) of lobular inflammation (%)
0 0.0 0.0 0.0 0.0 0.24 0.12 0.36
> 0 and < 2 48.2 38.1 32.5 39.7
2-4 41.0 42.9 53.8 45.8
> 4 10.8 19.0 13.8 14.6
Grade - mean±SD 1.6 1.8 1.8 1.7±0.7
Portal, chronic inflammation (%)
None 20.5 15.7 17.5 17.8 0.71 0.89 0.93
Mild 61.4 63.9 63.8 63.2
More than mild 18.1 20.5 18.8 19.0
Ballooning degeneration (%)
None 16.9 17.9 27.5 20.6 0.78 0.26 0.24
Few 36.1 31.0 32.5 33.2
Many 47.0 51.2 40.0 46.2
Grade - mean±SD 1.3 1.3 1.1 1.2±0.8
Supplement Table 1. Baseline characteristics by treatment group
P*
Vitamin Vitamin E Pioglitazone Vitamin E
Placebo E Pioglitazone Total vs. vs. vs.
(n=83) (n=84) (n=80) (n=247) Placebo Placebo Pioglitazone
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Total NAFLD Activity Score (%)
2 1.2 6.0 3.8 3.6 0.17 0.32 0.45
3 18.1 6.0 13.8 12.6
4 27.7 23.8 17.5 23.1
5 19.3 23.8 32.5 25.1
6 20.5 22.6 16.2 19.8
7 12.0 15.5 13.8 13.8
8 1.2 2.4 2.5 2.0
Grade - mean±SD 4.8 5.1 5.0 4.9±1.4 0.17 0.46 0.55
Biopsy length
(mm) - mean±SD 18.6 21.4 19.6 19.8±9.3 0.05 0.45 0.25
% < 10 mm 6.0 12.0 12.7 10.2 0.18 0.15 0.91
Iron status - mean±SD
Serum iron (ìg/dL) 89 90 103 94±36 0.87 0.03 0.03
Serum total iron binding
 capacity (ìg/dL) 359 360 356 358±70 0.94 0.83 0.78
Serum ferritin (ng/mL) 304 223 280 269±313 0.10 0.66 0.17
Dietary supplements (%)
Milk thistle 4.8 6.0 1.2 4.0 0.75 0.19 0.11
Green tea or green tea extract 1.2 0.0 0.0 0.4 0.31 0.32 --
Selenium 1.2 0.0 0.0 0.4 0.31 0.32 --
Vitamin A 2.4 1.2 0.0 1.2 0.55 0.16 0.33
Vitamin C 12.0 13.1 10.0 11.7 0.84 0.68 0.54
Vitamin D 3.6 7.1 10.0 6.9 0.31 0.10 0.51
*Based on chi-square test for categorical variables or t-test on rank of outcome for continuous variables
†SF-36 standardized to 1998 U.S. general population with mean=50 and SD =10
‡Missing values (4 Placebo, 5 Vitamin E, 6 Pioglitazone) due to patient being heavier than allowed weight were
imputed with the 95  percentileth
Supplement Table 2. Selected characteristics at week 96 by treatment group
P*
Vitamin E Pioglitazone Vitamin E
Vitamin vs. vs. vs.
Placebo E Pioglitazone Total Placebo Placebo Pioglitazone
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Dietary supplements (%)
n 74 79 70 223
Milk thistle 0.0 0.0 0.0 0.0 -- -- --
Green tea or green tea extract 2.7 0.0 0.0 0.9 0.14 0.17 --
Selenium 0.0 0.0 1.4 0.4 -- 0.30 0.29
Vitamin A 1.4 0.0 0.0 0.4 0.30 0.33 --
Vitamin C 4.0 10.1 5.7 6.7 0.15 0.64 0.32
Vitamin D 8.1 10.1 8.6 9.0 0.67 0.92 0.75
Liver histology
Biopsy length
n 72 80 70 222
(mm) - mean±SD 18.6 17.1 18.6 18.1±9.4 0.24 0.99 0.32
% < 10 mm 9.7 8.8 12.9 10.4 0.84 0.55 0.42
*Based on chi-square test for categorical variables or t-test on for continuous variables
Supplement Table 3. Clinic events, outcomes and adverse events by treatment group
P
Vitamin E Pioglitazone
Placebo Vitamin E Pioglitazone vs. vs.
(n=83) (n=84) (n=80) Placebo Placebo
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Clinical events / outcomes
Hypoglycemia 8 8 15 1.00 0.11
New-onset diabetes 0 4 0 0.12 -.-
Cardiovascular event 12 12 10 1.00 0.82
Bone fracture 5 3 3 0.50 0.50
Weight gain > 20% from baseline 0 0 3 -.- 0.12
Bone mineral density loss
$ 1 t-score from baseline* 0 0 1 -.- 0.47
Hepatotoxicity
ALT > 250 U/L 1 4 0 0.37 1.00
ALT > 500 U/L 0 0 0 -.- -.-
AST > 250 U/L 3 1 1 0.37 0.62
GGT > 250 U/L 2 1 1 0.62 1.00
Bilirubin > 3 mg/dL 0 1 2 1.00 0.24
Adverse events by severity† 0.77 0.51
Mild 20 24 25
Moderate 20 19 16
Severe 10 7 2
Arthritis 0 0 1
Hepatotoxicity 3 0 0
Cataract 1 0 0
Fracture 2 0 0
Gastroenteritis 0 1 0
Gout 1 0 0
Hyperglycemia 0 1 0
Infection 2 0 0
Pain 1 3 0
Syncope 0 1 0
Transient ischemic attack 0 0 1
Urticaria 0 1 0
Life-threatening or disabling 0 2 0
Cardiac ischemia/infarction 0 1 0
Liver dysfunction 0 1 0
Death‡ 0 1 0
Total 50 53 43
*Number of patients with DEXA scan at both week 96 and baseline are 50, 51, and 49 for placebo, vitamin E and
pioglitazone groups respectively
†As reported by study physician at time of event
‡Cause of death was pneumonia and liver failure secondary to sepsis from gram-negative bacteremia 
Supplement Table 4. Changes from baseline to 96 weeks in symptoms of liver disease*
P‡
Change in degree of bother† Vitamin E Pioglitazone Vitamin E
Placebo Vitamin E Pioglitazone vs vs vs
Symptom of liver disease (n=74) (n=77) (n=70) Placebo Placebo Pioglitazone
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Pain over liver (right upper quadrant) -0.07 -0.08 -0.09 0.55 0.53 0.97
Nausea -0.12 -0.10 0.03 0.17 0.79 0.29
Poor appetite -0.01 -0.05 0.24 0.35 0.51 0.05
Fatigue -0.03 -0.14 -0.03 0.37 0.66 0.70
Weight loss 0.03 0.04 -0.11 0.68 0.62 0.33
Diarrhea -0.16 0.04 -0.03 0.70 0.77 0.57
Muscle aches or cramps 0.03 0.12 0.27 0.95 0.29 0.44
Muscle weakness 0.00 0.23 0.09 0.56 0.77 0.36
Headaches 0.11 0.18 0.29 0.92 0.65 0.78
Easy bruising -0.03 -0.12 0.14 0.46 0.57 0.24
Itching -0.01 0.08 0.21 0.73 0.28 0.42
Irritability 0.15 0.08 0.27 0.18 0.42 0.04
Depression / sadness 0.20 -0.06 0.28 0.05 0.61 0.02
Trouble sleeping 0.24 0.09 0.27 0.17 0.64 0.46
Trouble concentrating 0.15 0.05 0.28 0.46 0.73 0.27
Jaundice 0.08 0.01 0.09 0.22 0.95 0.36
Dark urine 0.05 -0.09 0.00 0.19 0.46 0.57
Swelling of ankles 0.14 -0.01 0.29 0.26 0.22 0.01
Swelling of abdomen -0.08 0.01 -0.01 0.62 0.74 0.87
*Question on Symptoms of Liver Disease form: "During the last month, how much have you been bothered by the
following"
†Degree of bother coded as 1=none at all, 2=a little bit, 3=moderately, 4=quite a bit, 5=extremely
‡Based on ANCOVA model regressing change from baseline at 96 weeks on treatment group and baseline value of
the outcome
Supplement Table 5. Improvement in NASH and changes in other histologic features by treatment group
P*
Vitamin E Pioglitazone Vitamin E
W eek 96 - Baseline vs. vs. vs.
Placebo Vitamin E Pioglitazone Total Placebo Placebo Pioglitazone
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Primary outcome: Histologic improvement in NASH†
Number randomized 83 84 80 247
Percent improved 19 43 34 32 0.001 0.04 0.20
Changes in liver histology, baseline to 96 weeks
Number with two biopsies 72 80 70 222
Fibrosis
% worse 22 19 17 19 0.27 0.13 0.64
% same 47 41 39 42
% better 31 41 44 38
Mean change -0.1 -0.3 -0.4 -0.3 0.19 0.10 0.78
Steatosis
% worse 21 8 4 11 0.001 <0.0001 0.07
% same 49 39 27 38
% better 31 54 69 51
Mean change -0.1 -0.7 -0.8 -0.6 <0.0001 <0.0001 0.41
Lobular inflammation
% worse 17 8 6 10 0.01 0.001 0.43
% same 49 39 34 41
% better 35 54 60 50
Mean change -0.2 -0.6 -0.7 -0.5 0.008 0.0009 0.59
Portal inflammation
% worse 22 19 13 18 0.30 0.13 0.66
% same 67 64 71 67
% better 11 18 16 15
Ballooning degeneration
% worse 21 14 9 14 0.02 0.02 0.96
% same 50 36 47 44
% better 29 50 44 41
Mean change -0.2 -0.5 -0.4 -0.4 0.03 0.01 0.59
Total NAFLD Activity Score
% worse 31 11 9 17 0.0007 <0.0001 0.39
% same 19 14 10 14
% better 50 75 81 69
Mean change -0.5 -1.9 -1.9 -1.5 <0.0001 <0.0001 0.27
Diagnosis of NASH
% worse 12 4 7 8 0.0008 0.01 0.55
% same 60 44 43 49
% better 28 52 50 44
% resolved‡ 21 36 47 35 0.05 0.001 0.19
*P-values derived from Mantel-Haenszel chi-square test stratified by clinic for primary outcome, Cochran’s chi-
square test for trend for ordered outcomes, chi-square test for binary outcomes, or ANCOVA model regressing
change from baseline at 96 weeks on treatment group and baseline value of the outcome for continuous outcomes
†Primary outcome is defined as 1) no worsening in fibrosis; and 2) improvement in ballooning; and either 3a)
NAFLD Activity Score # 3; or 3b) decrease in NAFLD Activity Score of at least 2 and improvement in lobular
inflammation or steatosis; 11 Placebo, 4 Vitamin E, and 10 Pioglitazone assigned patients with missing histology
at week 96 were imputed with no improvement.
Supplement Table 5. Improvement in NASH and changes in other histologic features by treatment group
P*
Vitamin E Pioglitazone Vitamin E
W eek 96 - Baseline vs. vs. vs.
Placebo Vitamin E Pioglitazone Total Placebo Placebo Pioglitazone
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‡Defined as no NASH at week 96
Supplement Table 6. Change from baseline at week 96 in serum biochemical tests, quality of life and
metabolic factors by treatment group
P*
W eek 96 - Baseline Vitamin E Pioglitazone Vitamin E
Placebo Vitamin E Pioglitazone Total vs. vs. vs.
(n=74) (n=78) (n=70) (n=222) Placebo Placebo Pioglitazone
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Change in serum enzymes and bilirubin, baseline to 96 weeks
AST (U/L) -3.8 -21.3 -20.4 -15.2 0.0001 <0.0001 0.30
ALT (U/L) -20.1 -37.0 -40.8 -32.6 0.001 <0.0001 0.19
GGT (U/L) -4.0 -14.0 -21.1 -12.9 0.003 0.0002 0.25
Alkaline phosphatase (U/L) -3.8 -9.3 -12.0 -8.3 0.008 0.004 0.87
Bilirubin - direct (mg/dL) 0.022 0.043 -0.003 0.022 0.43 0.90 0.38
Bilirubin - total (mg/dL) 0.064 0.037 -0.040 0.022 0.56 0.07 0.23
Change in lipids, baseline to 96 weeks
Triglycerides (mg/dL) -6.7 -0.6 -19.8 -8.6 0.45 0.16 0.07
Total cholesterol (mg/dL) -9.6 -13.6 -11.4 -11.6 0.25 0.50 0.51
High density lipoprotein (mg/dL) -1.9 -0.9 1.1 -0.6 0.51 0.008 0.17
Low density lipoprotein (mg/dL) -5.8 -12.0 -8.1 -8.7 0.07 0.26 0.33
Change in metabolic characteristics, baseline to 96 weeks
HOMA-IR† (mg/dL × ìU/mL/405) 0.4 0.4 -0.7 -0.2 0.80 0.03 0.02
Fasting serum glucose (mg/dL) 1.8 1.8 -3.1 0.2 0.81 0.006 0.008
Fasting serum insulin (ìU/mL) 1.8 0.6 -2.0 -1.0 0.76 0.06 0.04
Weight (kg) 0.7 0.4 4.7 1.8 0.65 0.0001 <0.0001
Body mass index (kg/m ) 0.4 0.1 1.8 0.7 0.50 0.0002 <0.00012
Waist circumference (cm) 0.2 -0.4 3.3 1.0 0.53 0.06 0.03
Waist to hip ratio -0.0086 -0.0086 -0.0094 -0.0089 0.76 0.92 1.00
Triceps skinfold (mm) 0.6 -0.6 2.2 0.7 0.21 0.33 0.01
Mid-upper arm circumference (cm) 0.3 -0.2 1.3 0.4 0.27 0.02 0.01
Trunk (% fat) 0.5 0.6 1.6 0.9 0.89 0.12 0.12
Total (% fat) 0.0 0.4 2.7 1.0 0.50 <0.0001 0.0005
Change in quality of life measures, baseline to 96 weeks
Physical component¶
Physical function  -0.6  -0.6 -2.3  -1.1  0.95 0.45  0.49
Role physical -0.5 -0.3 -1.6 -0.8 0.58 0.85 0.83
Bodily pain -0.7 0.3 -1.4 -0.5 0.31 0.98 0.38
General health 1.7 1.6 0.8 1.3 0.78 0.59 0.43
Physical component summary -0.3 0.4 -0.9 -0.3 0.45 0.93 0.54
Mental component¶
Vitality 0.7 1.2 -0.3 0.6 0.33 0.84 0.32
Social function -0.7 -2.0 -3.0 -1.9 0.62 0.22 0.50
Role emotional 0.4 -0.4 -2.2 -0.7 0.66 0.48 0.81
Mental health 0.1 -0.5 -1.6 -0.7 0.90 0.24 0.38
Mental component summary 0.4 -0.5 -1.9 -0.6 0.76 0.23 0.47
*P-values derived from ANCOVA model regressing change from baseline at 96 weeks on treatment group and
baseline value of the outcome
†Four patients assigned to Vitamin E developed new onset diabetes; Their HOMA-IR values at 96 weeks were
imputed with the 95  percentile value at baseline. Analyses using ranks were used due to asymmetry in theth
distribution of change in HOMA-IR and fasting serum insulin.
¶SF-36 standardized to 1998 US general population with mean=50 and SD=10
Supplement Table 7. Changes in serum biochemical tests, metabolic factors, and quality of life after 96 weeks
of treatment and after 120 weeks (96 weeks of treatment followed by 24 weeks off-treatment)
P*
Vitamin E Pioglitazone
Placebo Vitamin E Pioglitazone vs. vs.
Placebo Placebo
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Number of paired observations
Baseline to 96 weeks 74 78 70
Baseline to 120 weeks 68 71 63
Change in serum enzymes and bilirubin
ALT (U/L)
Baseline to 96 weeks -20.1 -37.0 -40.8 0.001 <0.0001
Baseline to 120 weeks           -26.0 -19.7 -24.8 0.41 0.58
AST (U/L)
Baseline to 96 weeks -3.8 -21.3 -20.4 0.0001 <0.0001
Baseline to 120 weeks -10.5 -12.5 -12.2 0.85 0.25
GGT (U/L)
Baseline to 96 weeks -4.0 -14.0 -21.1 0.003 0.0002
Baseline to 120 weeks NA NA NA
Alkaline phosphatase (U/L)
Baseline to 96 weeks -3.8 -9.3 -12.0 0.008 0.004
Baseline to 120 weeks -4.8 -8.3 -4.2 0.05 0.59
Bilirubin - total (mg/dL)
Baseline to 96 weeks 0.06 0.04 -0.04 0.56 0.07
Baseline to 120 weeks 0.04 0.09 0.01 0.53 0.41
Change in lipids
Triglycerides (mg/dL)
Baseline to 96 weeks -6.7 -0.6 -19.8 0.45 0.16
Baseline to 120 weeks -8.6 0.4 -4.1 0.42 0.77
Cholesterol (mg/dL)
Baseline to 96 weeks -9.6 -13.6 -11.4 0.25 0.50
Baseline to 120 weeks -13.4 -16.5 -15.4 0.28 0.42 
High density lipoprotein (mg/dL)
Baseline to 96 weeks -1.9 -0.9 1.1 0.51 0.008
Baseline to 120 weeks -1.7 -0.9 -2.0 0.61 0.92
Low density lipoprotein (mg/dL)
Baseline to 96 weeks -5.8 -12.0 -8.1 0.07 0.26
Baseline to 120 weeks -10.0 -13.3 -11.9 0.16 0.26
Change in metabolic characteristics
Fasting serum glucose (mg/dL)
Baseline to 96 weeks 1.8 1.8 -3.1 0.81 0.006
Baseline to 120 weeks 2.0 2.7 1.9 0.45 0.66
HOMA-IR† ([mg/dL × ìU/mL]/405)
Baseline to 96 weeks 0.4 0.4 -0.7 0.80 0.03
Baseline to 120 weeks 0.1 0.4 0.2 0.24 0.42
Weight (kg)
Baseline to 96 weeks 0.7 0.4 4.7 0.65 0.0001
Baseline to 120 weeks 0.9 -0.4 3.7 0.21 0.008
Body mass index (kg/m )2
Baseline to 96 weeks 0.4 0.1 1.8 0.50 0.0002
Supplement Table 7. Changes in serum biochemical tests, metabolic factors, and quality of life after 96 weeks
of treatment and after 120 weeks (96 weeks of treatment followed by 24 weeks off-treatment)
P*
Vitamin E Pioglitazone
Placebo Vitamin E Pioglitazone vs. vs.
Placebo Placebo
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Baseline to 120 weeks 0.4 -0.2 1.4 0.16 0.006
Waist circumference (cm)
Baseline to 96 weeks 0.2 -0.4 3.3 0.53 0.06
Baseline to 120 weeks 1.6 -0.6 2.9 0.05 0.19
Body composition (% fat)
Baseline to 96 weeks 0.0 0.4 2.7 0.50 <0.0001
Baseline to 120 weeks -0.1 0.1 1.7 0.69 0.002
Change in quality of life measures
SF-36‡ Physical component summary
Baseline to 96 weeks -0.3 0.4 -0.9 0.45 0.93
Baseline to 120 weeks -1.3 -0.0 -1.0 0.15 0.46
SF-36‡ Mental component summary
Baseline to 96 weeks 0.4 -0.5 -1.9 0.76 0.23
Baseline to 120 weeks 0.7 1.0 -2.5 0.60 0.11
*P-values derived from ANCOVA models regressing change from baseline to 96 weeks or 120 weeks on treatment
group and baseline value of the outcome measure
†Four patients assigned to Vitamin E developed new onset diabetes and were not given an oral glucose tolerance test
at 96 weeks or 120 weeks. Their HOMA-IR values at 96 weeks and 120 weeks were imputed with the 95 th
percentile value at baseline. Analyses using ranks were used due to asymmetry in the distribution of change in
HOMA-IR.
‡SF-36 standardized to 1998 US general population with mean=50 and SD=10
Supplement Table 8. Sensitivity analyses
P*
Histologic improvement Vitamin E Pioglitazone Vitamin E
Placebo Vitamin E Pioglitazone vs vs vs
%    N %    N %    N Placebo Placebo Pioglitazone
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Primary outcome as stated in protocol
Missed week 96 biopsies
imputed as no improvement 19% 83 43% 84 34% 80 0.001 0.04 0.20
Sensitivity analyses
Exclude if missed 22% 72 45% 80 39% 70 0.004 0.05 0.38
Exclude if missed or outside time
window 21% 70 45% 76 38% 66 0.003 0.04 0.39
Exclude if no ballooning at baseline 23% 69 52% 69 47% 58 0.0004 0.002 0.41
Redefine ballooning component
to no worsening for biopsies with
no ballooning at baseline 25% 83 51% 84 48% 80 0.0007 0.003 0.59
Redefine ballooning component
and exclude if missed 29% 72 54% 80 54% 70 0.003 0.004 0.98
Exclude if biopsy length < 10mm
at baseline or week 96 15% 73 39% 69 30% 63 0.001 0.03 0.28
Local reading at baseline, central reading at week 96
Overall 23% 83 48% 84 52% 80 0.0008 <0.0001 0.57
Exclude if missing 26% 72 50% 80 60% 70 0.004 <0.0001 0.23
Exclude if missing or outside time
window 27% 70 49% 76 61% 66 0.008 0.0001 0.13
P-values determined from three pairwise Mantel-Haenszel chi-square tests stratified by clinic
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Supplement Table 9: Multiple Imputation and Best/Worst Case Scenario for missing week 96 biopsy
Number of completed and missing week 96 biopsies
Vitamin E Placebo Pioglitazone
(n=84) (n=83) (n=80)
Completed week 96 biopsy 80 72 70
Missing week 96 biopsy 4 11 10
No ballooning on baseline biopsy* 2 2 2
Some ballooning on baseline biopsy† 2 9 8
*Imputed as no response in multiple imputation and best/worst case scenario imputations
†Available for multiple imputation and best/worst case scenario imputations
Regression analyses
Vitamin E vs. Placebo Pioglitazone vs. Placebo
OR* 95% CI P-value OR* 95% CI P-value
Per protocol† 3.1 1.6-6.3 0.001 2.1 1.0-4.3 0.04
Multiple imputation‡ 2.7 1.2-5.9 0.01 2.1 1.0-4.4 0.04
Worst case scenario¶ 1.7 0.9-3.3 0.09 1.2 0.6-2.3 0.62
Best case scenario§ 3.5 1.7-6.9 <0.001 3.3 1.6-6.6 0.001
*Odds ratio of histologic improvement estimated from logistic regression
†Observations with missing week 96 biopsy imputed as no improvement
‡Observations with missing week 96 biopsy and some ballooning at baseline were imputed using 50 datasets.
Imputation model included the following variables at baseline: treatment group indicator, ballooning,
inflammation, steatosis, NAFLD Activity score, and fibrosis.
¶Observations with missing week 96 biopsy and some ballooning at baseline were imputed as improvement for
patients assigned to Placebo and no improvement for patients assigned to either Vitamin E or Pioglitazone
§Observations with missing week 96 biopsy and some ballooning at baseline were imputed as no improvement for
patients assigned to Placebo and improvement for patients assigned to either Vitamin E or Pioglitazone
Supplement Table 10. Subgroup analyses
Interaction P*
Histologic improvement Vitamin E Pioglitazone Vitamin E
Placebo Vitamin E Pioglitazone vs vs vs
%    N %    N %    N Placebo Placebo Pioglitazone
15
Race†
White 14% 73 46% 67 32% 68 0.007 0.74 0.06
Non-white 56% 9 33% 12 67% 6
Gender
Female 16% 48 42% 52 36% 47 0.49 0.22 0.64
Male 26% 35 44% 32 30% 33
Age at baseline - yrs
< 46 15% 47 43% 46 36% 45 0.41 0.30 0.86
$ 46 25% 36 42% 38 31% 35
Ethnicity
Non-Hispanic 17% 77 43% 68 34% 65 0.15 0.13 0.93
Hispanic 50% 6 44% 16 33% 15
BMI at baseline - kg/m2
< 35 22% 49 50% 50 36% 47 0.56 0.92 0.53
$ 35 15% 33 34% 32 30% 33
NAS at baseline
2-4 18% 39 23% 30 29% 28 0.04 0.70 0.15
5-8 20% 44 54% 54 37% 52
Ballooning at baseline
None 0% 14 0% 15 0% 22 NA NA NA
Few or many 23% 69 52% 69 47% 58
Treatment adherence‡
< 80% 27% 11 44% 9 0% 8 0.77 0.02 0.09
$ 80% 21% 61 45% 71 44% 62
Treatment adherence‡
< 90% 30% 23 52% 21 36% 22 0.90 0.35 0.46
$ 90% 18% 49 42% 59 40% 48
*P-value determined from three pairwise logistic regressions of probability of histologic improvement on indicator
variables for treatment group, risk factor, and interaction of treatment group and risk factor
†1 Placebo, 5 Vitamin E, and 6 Pioglitazone patients had missing values for race
‡Patients missing a biopsy at 96 weeks were excluded; Defined as the percent of days from randomization to biopsy
at 96 weeks taking both drugs based on pill counts
